Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19
Dorien Feyaerts, Julien Hédou, Joshua Gillard, Han Chen, Eileen S. Tsai, Laura S. Peterson, Kazuo Ando, Monali Manohar, Evan Do, Gopal Krishna Dhondalay, Jessica Fitzpatrick, Maja Artandi, Iris Chang, Theo T. Snow, R. Sharon Chinthrajah, Christopher Warren, Richard Wittman, Justin Meyerowitz, Edward A. Ganio, Ina A. Stelzer, Xiaoyuan Han, Franck Verdonk, Dyani Gaudillière, Nilanjan Mukherjee, Amy S. Tsai, Kristen K. Rumer, Danielle R. Jacobsen, Zachary B. Bjornson-Hooper, Sizun Jiang, Sergio Fragoso Saavedra, Sergio Iván Valdés‐Ferrer, J. Daniel Kelly, David Furman, Nima Aghaeepour, Martin S. Angst, Scott D. Boyd, Benjamin A. Pinsky, Garry P. Nolan, Kari C. Nadeau, Brice Gaudillière, David R. McIlwain
Abstract
= 0.773, p = 7.7e-6). Examination of informative model features reveals biological signatures of COVID-19 severity, including the dysregulation of JAK/STAT, MAPK/mTOR, and nuclear factor κB (NF-κB) immune signaling networks in addition to recapitulating known hallmarks of COVID-19. These results provide a set of early determinants of COVID-19 severity that may point to therapeutic targets for prevention and/or treatment of COVID-19 progression.